Vaccines Market is segmented by Indication (Influenza, Rotavirus, DTP, COVID-19), Route of Administration (Intramuscular, Subcutaneous, Oral), Type/Antigen (Conjugate Vaccines, Live Attenuated Vaccines), and Valence (Multivalent, Monovalent Vaccines) and Geography.

The Vaccines Market is expected to reach a market size value of USD 119.7 billion by 2028 at a 10.9% CAGR.

Vaccines are substances utilized to improve the production of antibodies and supply enough immunity to various diseases derived from the activating agent of that disease, as well as treating it as an antigen without causing or triggering the disease itself. The vaccine safeguards against real pathogens by imitating the infection.

COVID-19 Impact Assessment

COVID-19 is a real challenge that all the industries need to deal with primarily because, during the onset of the outbreak, nations are struggling on how to control the widespread of the infections, so much so, the discovery of an effective vaccine. A vaccine is very significant in times of pandemic because it is the first and only defense against the threat of diseases. Without vaccines, infection will soon spread rapidly affecting every individual or laborers, and will have a relatively negative impact on every industry because every worker is disabled.

The growth of this market is mainly attributed to the prevalence of chronic diseases, support and initiatives from the government regarding immunization, advancements in technology relative to the vaccines market, vaccines pipeline dependability, and the impending dangers of COVID-19. It should also be added that there is an increase in epidemic potential, centered attention on therapeutic vaccines as well as rising numbers of emerging markets.

With the unfortunate event of the increasing rate of mortality brought upon by the pandemic, the demand, and surge for the need for vaccines mainly triggered the growth of this market. To name a few restraints on this market, product recalls as well as lacking access to vaccines are factors that pull back the growth of the vaccines market. The delayed manufacturing of the vaccines is the biggest hindrance because normally, it will take up to 10-15 years to fully develop an effective vaccine. What happened in the market was, vaccine development and research are rushed to provide an immediate solution to the spread of the infection.

On a positive note, the market for vaccines has exponentially grown globally due to the governments prioritization of immunization programs. Many governments are also in partnership with private sectors to promote and push further the development of vaccines and their roll out.

Key Findings in the Vaccines Market

The Pneumococcal Diseases Segment is expected to have the largest share in the market in 2021 because there is a high number of pneumococcal diseases like pneumonia, meningitis, febrile bacteremia, otitis media, and sinusitis. Developing a quality vaccine, and government initiatives, and support to impose stringent health protocols and controlling the outbreaks of such diseases are considered to be the factors attributing to this markets growth.

Subcutaneous Route of Vaccine Administration Segment is anticipated to have the fastest growth during the forecast period. The growth is mainly caused by, better adsorption of the vaccine, trained professionals do not need any requirement, and the number of vaccinations sites sprouting in different regions. Self-administration by the patients also contributed to the growth of the said market.

In terms of valence, the Polyvalent (Multivalent) Vaccines is projected to have the largest share in the market in 2021 mainly attributing to factors of growth such as new launches of multivalent vaccines, numerous investments are done by key players, focus on the research and development, and technological developments in the production of this segment of the vaccine. 

Regional Market Analysis

In terms of region segment, the Vaccines market is further classified into North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. North America is expected to dominate and command to have the largest share in the market. The next on the list would be Asia-Pacific, Europe, Latin America, and the Middle East & Africa. During the forecast period, Asia Pacific, on the other hand, is expected to be the fastest-growing regional market owing to it to the factors such as the high number of infectious disease cases, higher population suffering from diseases, social awareness on the benefits, and information on the vaccines, and governments immediately pushing forth the immunization globally.

Key Players: Share and Competition

Based on an extensive assessment, these major key players in the vaccines market have a competitive landscape and utilizing key strategic developments to lead the industry over the past years until now. These companies are, Sanofi (France), Merck & Co., Inc. (U.S.), GlaxoSmithKline plc (U.K.), Pfizer Inc. (U.S.), Johnson & Johnson (U.S.), Daiichi Sankyo Co., Ltd. (Japan), Takeda Pharmaceutical Company Limited (Japan), CSL Limited (Australia), Emergent BioSolutions Inc. (U.S.), and AstraZeneca PLC (U.K.).

Report Highlights
• Historical data available (as per request)
• Estimation/projections/forecast for revenue and unit sales (2021 – 2028)
• Data breakdown for every market segment (2021 – 2028)
• Gross margin and profitability analysis of companies
• Price analysis of each product type
• Business trend and expansion analysis
• Import and export analysis
• Competition analysis/market share
• Supply chain analysis
• Client list and case studies
• Market entry strategy

Industry Segmentation and Revenue Breakdown

Indication Analysis (Revenue, USD Million, 2021 - 2028)

• Pneumococcal Diseases
• Influenza
• Human Papillomavirus (HPV)
• DTP
• Meningococcal Disease
• MMR
• Rotavirus
• Poliomyelitis (Polio)
• Hepatitis
• COVID-19
• Other Indications
(Note: Other Indications Include Varicella, Herpes Zoster, Chlorella, Severe Acute Respiratory Syndrome, and Rabies)

Route of Administration Analysis (Revenue, USD Million, 2021 - 2028)

• Intramuscular
• Subcutaneous
• Oral
• Intradermal
• Nasal

Type/Antigen Analysis (Revenue, USD Million, 2021 - 2028)

• Live Attenuated Vaccines
• Inactivated Vaccines
• Subunit and Conjugate Vaccines
• Toxoid Vaccines
• Combination Vaccines

Valence Analysis (Revenue, USD Million, 2021 - 2028)

• Monovalent Vaccines
• Polyvalent (Multivalent) Vaccines

Region Analysis (Revenue, USD Million, 2020 – 2028)

• United States
• Canada
• Mexico
• France
• Germany
• Italy
• Spain
• United Kingdom
• Russia
• China
• India
• Philippines
• Malaysia
• Australia
• Austria
• South Korea
• UAE
• Qatar
• Saudi Arabia
• Japan
• Africa
• Rest of World

Available Versions:
• United States Vaccines Industry Research Report
• Europe Vaccines Industry Research Report
• Asia Pacific Vaccines Industry Research Report

Need report on this market for specific region or Country? Or need a customized report as per your need? Want to know discounts as available?

Email US

David Correa

david@marketdecipher.com

Or Fill the form below "Sample Request Form" with your queries in message box.